Advertisement


Tomasz Jankowski, MD, PhD, on Non–Small Cell Lung Cancer: New Data on a Telomere-Targeting Agent

2024 ASCO Annual Meeting

Advertisement

Tomasz Jankowski, MD, PhD, of Poland’s Medical University in Lublin, discusses a phase II study of THIO, a telomere-targeting agent followed by cemiplimab-rwlc for a difficult-to-treat population of patients with advanced non–small cell lung cancer (Abstract 8601).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
TIO represents a groundbreaking first-in-class, small molecule where directed targets telomeres in cancer cells. Specifically those telomeres positive with over 80% of all cancers, and approximately 78-83% of all non-small cell and cancer types being third positive. This innovative approach is particularly significant. TIO operates for a dual mechanism of action. Firstly, it targets telomeres by incorporating itself into newly synthesized telomeres, leading to chromatin uncapping, the generation of DNA damage signals and rapid apoptosis of cancer cells. Secondly, it has an immunogenic effect that enhances the body's immune response against the tumor. In preclinical models sequential treatment with TIO and immune checkpoint inhibitors has demonstrated potent and durable anti-tumor activity, for instance, in non-small cell lung cancer, combining TIO with atezolizumab resulted in a 60% complete response rate with an anti-cancer [inaudible 00:01:08]. In colorectal cancer achieved 100% complete responses with similar promising results in small cell and cancer as well as in hepatocellolar carcinoma. Turning our attention to the TIO-101 trial, it's a phase two dose optimization study for adult patients with advanced or metastatic non-small cell lung cancer who progress or relapse after one to four prior treatments, including immuno and platinum chemotherapy. Using assignment to stage design, 79 patients were assigned to receive one of three doses of TIO. 360, 180 or 60 milligrams, followed by semi-primab every three weeks for up to a year. The combination of TIO and semi-primab has been well tolerated by this heavily pre-treated patients. We have observed significant activity in this difficult to treat group, including both resistant to checkpoint inhibitors and chemotherapy. Importantly, the presence of TIO in circulating tumor cells has shown on target effects. In November, 2023, the ongoing phase two study identified with 180 milligram dose of TIO is the optimal dose, demonstrating better safety and superior efficacy compared to other doses. Specifically, only 9.8% of patients receiving 180 milligram dose reported grade three adverse events related to treatment with no grade four or five adverse events. Per safety profile suggests that TIO could potentially offer a far better alternative to chemotherapy. In terms of efficacy in the third line setting, disease control rate reached 85% for TIO with semi-primab comparing to 25-35% typically observed with standard chemotherapy. We have also seen long-term responses. With five patients having survival follow up for over 12 months, three of them are still on treatment. The median survey will follow up in the third line is 9.1 months. Moreover, overall response rate in the third line with dose 180 milligrams of TIO was 38%, comparing to about 6% for other treatment possibilities. In conclusion, the safety and efficacy achievements of TIO are truly promising. We are confirming many of the assumptions [inaudible 00:03:18] observed in the pre-clinical studies, and we are looking forward to follow up our patients.

Related Videos

Gastroesophageal Cancer

Jens Marquardt, MD, and Jens Hoeppner, MD, on Esophageal Cancer: Phase III Findings on Chemotherapy vs Chemoradiation

Jens Marquardt, MD, of the University of Lübeck, and Jens Hoeppner, MD, of the University of Bielefeld, discuss findings from the ESOPEC trial, which showed that perioperative chemotherapy (fluorouracii, leucovorin, oxaliplatin, docetaxel) and surgery improves survival in patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation (41.4 Gy plus carboplatin and paclitaxel) followed by surgery (LBA1).

Colorectal Cancer

Andrea Cercek, MD, on Rectal Cancer: Durable Complete Responses to PD-1 Blockade Alone

Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, discusses expanded data on the durability of complete response to dostarlimab-gxly, a PD-1 single-agent therapy administered to patients with locally advanced mismatch repair–deficient rectal cancer. The drug yielded recurrence-free responses, lasting longer than a year, without the need for chemotherapy, radiation, or surgery (LBA3512).

Gynecologic Cancers

Alex Andrea Francoeur, MD, on Endometrial Cancer and Obesity Trends

Alex Andrea Francoeur, MD, of UC Irvine Health, discusses data showing an association between the increasing incidence of endometrial cancer and obesity, which disproportionately affects younger women and women of color. According to Dr. Francoeur, the findings warrant targeted health services and public health interventions to stabilize and ultimately reverse the rising rates (Abstract 5507).

Multiple Myeloma

Paula Rodríguez-Otero, MD, PhD, and Amrita Y. Krishnan, MD, on Multiple Myeloma: Moving BCMA-Directed Therapies to Earlier Use

Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, and Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, discuss two key studies on B-cell maturation antigen (BCMA)-directed therapies: CARTITUDE-4 on ciltacabtagene autoleucel in patients with functional high-risk multiple myeloma; and DREAMM-7 on belantamab mafodotin-blmf plus bortezomib and dexamethasone vs daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory disease.

Skin Cancer

Pauline Funchain, MD, and Caroline Robert, MD, PhD, on Melanoma: New Data on Encorafenib, Binimetinib, Ipilimumab, and Nivolumab

Pauline Funchain, MD, of Stanford University, and Caroline Robert, MD, PhD, of Gustave Roussy, discuss phase II findings showing that combining encorafenib and binimetinib followed by ipilimumab and nivolumab vs ipilimumab and nivolumab can improve progression-free survival in patients with BRAF-V600E/K-mutated melanoma characterized by high lactate dehydrogenase and liver metastases (Abstract LBA9503).

Advertisement

Advertisement




Advertisement